The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Race Matters in COVID-19 Outcomes for Patients with Rheumatic Disease

Race Matters in COVID-19 Outcomes for Patients with Rheumatic Disease

February 24, 2021 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Introduction & Objectives
People with rheumatic disease, particularly those receiving immunosuppressive medications, have a higher risk of developing severe infections. Therefore, several reports have examined the prevalence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases. Most literature suggests a prevalence of COVID-19 in the rheumatic disease population similar to that in the general population, but one study indicated a slightly higher risk of mortality in individuals with rheumatic diseases, and some immunosuppressive medications may place patients at higher risk of hospitalization. Rheumatic disease patients with comorbidities also have higher odds of poor outcomes.

You Might Also Like
  • COVID-19 Risks & Treatment for Patients with Rheumatic Disease
  • COVID-19: Most Individuals with Rheumatic Disease Recover
  • Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19

Research has illustrated the disproportionate burden of COVID-19 in racial/ethnic minority populations. COVID-19-related deaths are significantly higher in communities with higher proportions of Black, Latinx, Asian American or other racial/ethnic minorities.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This study was undertaken to examine the association between race/ethnicity and COVID-19 hospitalization, ventilation status and mortality in people with rheumatic disease.

Methods
U.S. patients with rheumatic disease and COVID-19 entered into the COVID-19 Global Rheumatology Alliance physician registry between March 24, 2020, and Aug. 26, 2020, were included in this analysis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Physicians indicated whether the diagnosis of COVID-19 was based on polymerase chain reaction, antibody testing, metagenomic testing, computed tomography scan, laboratory assay or a presumptive diagnosis based only on characteristic symptoms.

Race/ethnicity was reported by the physician entering the case, and multiple categories could be selected. The researchers defined race/ethnicity as white, Black, Latinx, Asian or other/mixed race.

Outcome measures included hospitalization, requirement for ventilatory support and death. Multivariable regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) adjusted for age, sex, smoking status, rheumatic disease diagnosis, comorbidities, medication use prior to infection and rheumatic disease activity.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Results
A total of 1,324 patients were included in this study, of whom 36% were hospitalized and 6% died; 26% of hospitalized patients required mechanical ventilation. In multivariable models, Black patients (OR 2.74 [95% CI 1.90–3.95]), Latinx patients (OR 1.71 [95% CI 1.18–2.49]) and Asian patients (OR 2.69 [95% CI 1.16–6.24]) had higher odds of hospitalization than white patients. Latinx patients also had threefold increased odds of requiring ventilatory support (OR 3.25 [95% CI 1.75–6.05]). No differences in mortality based on race/ethnicity were found, although power may have been limited to detect associations.

Conclusion
Similar to findings in the general U.S. population, racial/ethnic minorities with rheumatic disease and COVID-19 had increased odds of hospitalization and ventilatory support. These results illustrate significant health disparities related to COVID-19 in people with rheumatic diseases.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: Arthritis & Rheumatology, COVID-19, ethnicity, race

You Might Also Like:
  • COVID-19 Risks & Treatment for Patients with Rheumatic Disease
  • COVID-19: Most Individuals with Rheumatic Disease Recover
  • Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19
  • Respiratory Failure More Common in COVID-19 Patients with Rheumatic Disease

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)